Clinical trials: Rhegmatogenous Retinal Detachment - Macula Off
- Condition Rhegmatogenous Retinal Detachment - Macula Off
- Funder type Industry (pharma, biotech, devices)
Rhegmatogenous Retinal Detachment - Macula Off
Acute Retinal Detachment Repair With the iSeelr™ Retinal Detachment Repair System
This study is a first-in-human clinical trial testing a new treatment for rhegmatogenous retinal detachments. The new treatment called retinal thermofusion uses a special laser device called iSeelr™ during surgery.
- Trial name
- NCT06468397
- Testing
- iSeelr™
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Photofuse Pty Ltd
Rhegmatogenous Retinal Detachment - Macula Off
A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
The purpose of this study is to evaluate the safety and tolerability of ONL1204 in participants with Macula-off, Rhegmatogenous Retinal Detachment (RRD).
- Trial name
- NCT03780972
- Testing
- ONL1204, Intravitreal Injection, Collection of ocular fluids
- Where
- 4 sites in Australia
- Volunteers
- 14 people
- Sponsor
- ONL Therapeutics
Rhegmatogenous Retinal Detachment - Macula Off
A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment
The goal of this Phase 2 clinical trial is to learn about ONL1204 Ophthalmic Solution in terms of safety and how well the drug works in patients that have a macula-off (central point of vision) rhegmatogenous retinal detachment…
- Trial name
- NCT05730218
- Testing
- ONL1204 Ophthalmic Solution
- Where
- 36 sites in United States
- Volunteers
- 136 people
- Sponsor
- ONL Therapeutics
Rhegmatogenous Macula-off Retinal Detachment
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
- Trial name
- NCT00972374
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 6 sites in United States, India and 4 more
- Volunteers
- 44 people
- Sponsor
- Allergan